Publication

Abstract : Background Metabolism dysfunction-associated steatotic liver disease (MASLD) is hepatic steatosis along with increased weight or obesity, type 2 diabetes, or metabolic dysregulation and without significant alcohol consumption. The clinical prediction of MASLD using simple, non-invasive indices like Fatty Liver Index (FLI), NAFLD Liver Fat Score (NAFLD LFS), Visceral Adiposity Index (VAI), Steato Test and Hepatic Steatosis Index (HSI) yielded heterogeneous results in different populations. Aim We aimed to compare five scores (Fatty Liver Index, NAFLD Liver Fat Score, Visceral Adiposity Index, Steato Test, Hepatic Steatosis Index) for prediction of liver steatosis. Method Patients with metabolic syndrome and alcohol intake less than 20 grams per day were included in the study. Patients with alcohol intake greater than 20 grams per day and known history of liver or biliary disease, infections, muscle injury, autoimmune diseases, thyroid disorders, underlying secondary diabetes mellitus, secondary hypertension, familial dyslipidemia, intake of medications like steroids, hepatotoxic drugs, chemotherapy or drugs altering liver function tests were excluded. The presence of fatty liver was confirmed on ultrasound. Five indices (Fatty Liver Index, NAFLD Liver Fat Score, Visceral Adiposity Index, Steato Test, Hepatic Steatosis Index) were applied to predict liver steatosis. The correlation of each index with presence of fatty liver was analyzed. Based on the sensitivity of the five scoring systems and prevalence of MASLD as observed in existing literature, with a 95% confidence interval and 20% allowable error, the minimum number of positive cases required is 24 and minimum sample size required is 77. Results Among 100 (100%) patients with metabolic syndrome, MASLD was seen in 65 patients (74% males, 56% females). The mean age of patients with MASLD was 59 years. Fatty Liver Index, NAFLD Liver Fat Score, Visceral Adiposity Index, Steato Test had statistically significant (p<0.005) correlation with fatty liver on ultrasound of abdomen. Fatty Liver Index had the highest Area Under the Receiver Operating Characteristic curve (AUROC) of 0.65 (Sensitivity=63, Specificity=62.9%), followed by NAFLD Liver Fat Score (AUROC=0.63, Sensitivity=64.4%, Specificity=62.9%), Visceral Adiposity Index (AUROC=0.628, Sensitivity=50.8%, Specificity=65.7%) and Steato Test (AUROC=0.61, Sensitivity=46.2%, Specificity=77%). Cut-offs for Fatty Liver Index, NAFLD Liver Fat Score, Visceral Adiposity Index, and Steato Test were 42, 0.5, 4, and 4.5 respectively. MASLD was present in 71.4% (N=35) of patients with type 2 diabetes mellitus and 58.8% (N=30) without type 2 diabetes mellitus. Conclusion Fatty Liver Index, NAFLD Liver Fat Score, Visceral Adiposity Index, and Steato Test were comparable as early markers to predict liver steatosis in patients with metabolic syndrome.